A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
- PMID: 35263204
- DOI: 10.1080/10428194.2022.2045598
A phase II study of obinutuzumab in combination with ibrutinib for treatment of relapsed mantle cell lymphoma
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources